CNCR Loncar Cancer Immunotherapy ETF

No holdings information is available in our database.

CNCR Loncar Cancer Immunotherapy ETF

Seeks to track, before fees and expenses, the LCINDX index, an index of companies that develop therapies to treat cancer by harnessing the body’s own immune system. Immunotherapy is a transformational field within the biotechnology space that is expected to become the foundational treatment for cancer over the next ten years. The Index includes 25 companies chosen as follows: 1) five top large pharmaceutical companies who are working on cancer immunotherapy are chosen; 2) Next, the top 20 growth biotechnology companies in immunotherapy by market capitalization are added. All companies included in the Index must have a high strategic focus on immunotherapy. The Index is an equal-weighted index.

$17.66  +0.46 (2.66%)
As of 08/12/2022 16:00:00 EST     IEX book   CBOE book

ETF Information
Sponsor:     Loncar Funds
Category1:  US Equity
Category2:  Single industry
Category3:  Biotechnology
Morningstar category:  Health
Leverage factor:  1.00
Inception date:  10/13/2015
Index tracking method: Passive replication
Current yield:  11.58%
Historical average yield:  1.57%
Market cap:  $25,800,300
Average volume:  8,536
Fees:     0.7900%

Index Information
Loncar Cancer Immunotherapy Index
Index symbol:  LCINDX
Provider:   Loncar Investments
Index weighting:   Equal weighted
Index inception date:  03/18/2015
Backtesting data exists:   No
Number of holdings:  30  (as of 12/15/2017)
Strategy:  Equal weighting
Rebalanced:  Semi-annually
Reconstituted:  Semi-annually

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy